Business
Align Research Initiates Coverage
Align Research Initiates Coverage.
About this update from Valirx Plc
[{"type":"text","content":"\n \nRNS Number : 9602E ValiRx PLC 24 October 2018 \n\n \n \n \nVALIRX PLC\n(\"ValiRx\" or the \"Company\")\n \nALIGN RESEARCH INITIATES COVERAGE\nLondon, UK., 24 October 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, today welcomes the initiation of research with a 'Conviction Buy' stance and the first analyst report published by Align Research, an investment research company.\nA copy of the report is available at:\nhttp://www.alignresearch.co.uk/cpt-company/valirx/\n \n*** ENDS ***\n \nFor more information, please contact:\n\n\n\nValiRx plc\n\n\nTel: +44 (0) 20 3008 4416\nwww.valirx.com\n\n\n\n\nDr Satu Vainikka, Chief Executive\n\n\nTel: +44 (0) 20 3008 4416\n\n\n\n\nTarquin Edwards, Head of Communications.\n\n\nTel: +44 (0) 7879 458 364\[email protected]\n\n\n\n\n\n\n\n\n\n\n\n \n \nNotes for Editors \n \nAbout ValiRx\nValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in \"precision\" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.\n \nThe Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field. \n \nValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.\n \nUntil recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients. \n \nThe Company listed on the AIM Mar...